Patent
Described herein is an alpha-emitting radionuclide, 211 At, which has been incorporated into a selective sigma-2 ligand moiety to provide cytotoxic capabilities to a chemical compound. As described herein, a compound of formula (I), wherein R 1 -R 4 , m, and n are defined herein, was prepared and utilized in in vitro and in vivo tumor targeting of alpha-emitting sigma-2 ligand in a breast cancer model. In one embodiment, the compound is 5-( 211 At)—N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2,3-dimethoxybenzamide.
1. A compound of formula (I):
wherein:
m is 1 or 2;
n is 1 to 10;
R 1 to R 4 are at the 2-, 3-, 4-, 5-, or 6-position of the benzene ring and, independently, H, C 1 to C 6 alkyl, C 1 to C 6 alkoxy, C 1 to C 6 haloalkyl, halogen, C 1 to C 6 fluoroalkoxy, C 1 to C 6 thioalkyl, C 1 to C 6 thio-haloalkyl, NH 2 , C 1 to C 6 aminoalkyl, or —(OCH 2 CH 2 ) q —F;
q is 2 to 6;
or R 1 and R 2 ; R 2 and R 3 ; or R 3 and R 4 together form a 5- or 6-membered benzene ring substituted with H or 1 to 4 R 5 ;
211 At is at the 2-, 3-, 4-, 5- or 6-position of the benzene ring; and
R 5 is H, C 1 to C 6 alkyl, C 1 to C 6 alkoxy, C 1 to C 6 haloalkyl, halogen, C 1 to C 6 fluoroalkoxy, C 1 to C 6 thioalkyl, C 1 to C 6 thio-haloalkyl, NH 2 , C 1 to C 6 aminoalkyl, or —(OCH 2 CH 2 ) q —F;
with the proviso that two of R 1 -R 4 and 211 At do not occupy the same position on said benzene ring;
or a pharmaceutically acceptable salt or prodrug thereof.
2. The compound of claim 1 , of formula (II):
3. The compound of claim 1 , wherein said halogen is a radioactive isotope.
4. The compound of claim 1 , wherein R 1 is C 1 to C 6 fluoroalkoxy.
5. The compound of claim 3 , wherein R 1 is O(CH 2 ) p F and p is 1 to 10.
6. The compound of claim 1 , wherein n is 2 to 4.
7. The compound of claim 1 , of formula (III):
8. The compound of claim 1 , of formula (IV):
9. The compound of claim 1 , of formula (V):
10. The compound of claim 1 , of formula (VI):
11. The compound of claim 1 , of formula (VII):
12. The compound of claim 1 , of formula (VIII):
13. The compound of claim 1 , which is:
14. A compound which is 5-( 211 astatine)-N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2,3-dimethoxybenzamide, derivative, salt, or prodrug thereof.
15. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
16. A method of
reducing proliferation of cancer cells, or
sensitizing cancer cells to a chemotherapeutic;
said method comprising contacting said cells with a compound of claim 1 .
17. The method of claim 16 , further comprising administering radiation to said cells.
18. A method of treating cancer in a patient sensitizing a patient's cancer cells to a chemotherapeutic or administering radiotherapy to a patient, said method comprising administering a compound of claim 1 to said patient.
19. The method of claim 18 , wherein said cancer is a neuroendocrine cancer.
20. The method of claim 18 , wherein said cancer is of the prostate, head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, bladder, uterus, cervix, breast, ovaries, vagina, testicles, thyroid, blood, lymph nodes, kidney, liver, intestines, pancreas, brain, central nervous system, adrenal gland, neuroendocrine, or skin or a leukemia.
21. The method of claim 18 , further comprising administering radiation to said patient.
22. The method of claim 18 , wherein said compound is administered to said patient through intravenous, intra-arterial, intraperitoneal or intracavitary injection.
23. The method of claim 18 , comprising administering an amount of said compound having from about 0.01 to about 100 Curies of radiation.